Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells

  1. Åsa Wallén-Mackenzie1,
  2. Alexander Mata de Urquiza1,
  3. Susanna Petersson1,5,
  4. Francisco J. Rodriguez2,5,
  5. Stina Friling1,5,
  6. Joseph Wagner2,
  7. Peter Ordentlich3,
  8. Johan Lengqvist1,
  9. Richard A. Heyman3,
  10. Ernest Arenas2, and
  11. Thomas Perlmann1,4,6
  1. 1 The Ludwig Institute for Cancer Research, Stockholm Branch, S-171 77 Stockholm, Sweden
  2. 2 Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden
  3. 3 X-Ceptor Pharmaceuticals Inc., San Diego, California 92121, USA
  4. 4 Department of Cell and Molecular Biology, Karolinska Institutet, S-171 77 Stockholm, Sweden

Abstract

The retinoid X receptor (RXR) is essential as a common heterodimerization partner of several nuclear receptors (NRs). However, its function as a bona fide receptor for endogenous ligands has remained poorly understood. Such a role would depend on the existence of RXR activating ligands in vivo and on the ability of such ligands to influence relevant biological functions. Here we demonstrate the presence of endogenous RXR ligands in the embryonic central nervous system (CNS) and show that they can activate heterodimers formed between RXR and the orphan NR Nurr1 in vivo. Moreover, RXR ligands increase the number of surviving dopaminergic cells and other neurons in a process mediated by Nurr1-RXR heterodimers. These results provide evidence for a role of Nurr1 as a ligand-independent partner of RXR in its function as a bona fide ligand-activated NR. Finally, our findings identify RXR-Nurr1 heterodimers as a potential target in the treatment of neurodegenerative disease.

Keywords

Footnotes

  • Article published online ahead of print. Article and publication date are at http://www.genesdev.org/cgi/doi/10.1101/gad.276003.

  • 5 These authors contributed equally to this work.

  • 6 Corresponding author. E-MAIL Thomas.Perlmann{at}licr.ki.se; FAX 46-8-33-28-12.

    • Accepted October 28, 2003.
    • Received June 23, 2003.
| Table of Contents

Life Science Alliance